Patents by Inventor Leonard Charles Harrison
Leonard Charles Harrison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220185864Abstract: The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has ?-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.Type: ApplicationFiled: March 7, 2019Publication date: June 16, 2022Inventors: Leonard Charles HARRISON, Esther BANDALA- SANCHEZ, Ethan David GODDARD-BORGER, Nicolle Hannah PACKER, Shathili Abdulrahman MANSOUR
-
Patent number: 11123403Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: August 21, 2019Date of Patent: September 21, 2021Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Publication number: 20200078440Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: August 21, 2019Publication date: March 12, 2020Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
-
Patent number: 10413589Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type I diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: December 12, 2018Date of Patent: September 17, 2019Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Publication number: 20190192624Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: December 12, 2018Publication date: June 27, 2019Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Patent number: 10328124Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: May 9, 2018Date of Patent: June 25, 2019Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Publication number: 20180256679Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: May 9, 2018Publication date: September 13, 2018Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Patent number: 10010582Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: December 19, 2016Date of Patent: July 3, 2018Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Patent number: 9778269Abstract: The present disclosure relates to the use of a soluble CD52 glycoprotein in treating diseases regulated by effector T-cells, for example sepsis or multiple sclerosis. The present disclosure also relates to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: March 25, 2013Date of Patent: October 3, 2017Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Leonard Charles Harrison, Maryam Rashidi, Yuxia Zhang
-
Publication number: 20170232061Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: December 19, 2016Publication date: August 17, 2017Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
-
Patent number: 9585969Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: GrantFiled: November 15, 2012Date of Patent: March 7, 2017Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang
-
Publication number: 20150259412Abstract: The present disclosure relates to the use of a soluble CD52 glycoprotein in treating diseases regulated by effector T-cells, for example sepsis or multiple sclerosis. The present disclosure also relates to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: March 25, 2013Publication date: September 17, 2015Inventors: Leonard Charles Harrison, Maryam Rashidi, Yuxia Zhang
-
Publication number: 20140308209Abstract: The present disclosure relates to a soluble CD52 glycoprotein and its use in treating diseases regulated by effector T-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of CD52, and to diagnostic methods based on the detection of CD52 expression levels in a subject.Type: ApplicationFiled: November 15, 2012Publication date: October 16, 2014Inventors: Esther Bandala Sanchez, James Dromey, Leonard Charles Harrison, Yuxia Zhang, Maryam Rashidi
-
Patent number: 8075899Abstract: The present invention relates generally to the field of immunotherapy and immunodiagnosis of autoimmune conditions. More particularly, the present invention provides peptides of the A-chain of proinsulin or insulin, which are recognized by or are specific for proinsulin- or insulin-sensitized T-cells. The present invention further contemplates the use of the these agents in therapeutic and diagnostic applications for Type 1 diabetes.Type: GrantFiled: July 22, 2005Date of Patent: December 13, 2011Assignee: The Walter and Eliza Hall Institute of Medical ResearchInventors: Stuart Ian Mannering, Leonard Charles Harrison, Anthony Wayne Purcell, Nicholas A. Williamson
